





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :		A2	(11) International Publication Number:	WO 97/38699															
A61K 31/765			(43) International Publication Date: 23 October 1997 (23.10.97)																
(21) International Application Number:		PCT/US97/06150																	
(22) International Filing Date:		14 April 1997 (14.04.97)																	
(30) Priority Data:		15 April 1996 (15.04.96)	US																
(60) Parent Application or Grant																			
(63) Related by Continuation																			
US		08/632,275 (CON)																	
Filed on		15 April 1996 (15.04.96)																	
(71) Applicant (for all designated States except US): CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY doing business as CAROLINAS MEDICAL CENTER [US/US]; P.O. Box 32861, Charlotte, NC 32861 (US).																			
(72) Inventors; and																			
(75) Inventors/Applicants (for US only): GHIO, Andrew, J. [US/US]; 211 Brandermill Drive, Durham, NC 27713 (US). KENNEDY, Thomas, P. [US/US]; 213 Grande Drive, Richmond, VA 23229 (US).																			
(74) Agents: MCCOY, Michael, D. et al.; Bell, Seltzer, Park & Gibson, P.O. Drawer 34009, Charlotte, NC 28234 (US).																			
(54) Title: USE OF ALKYLARYL POLYETHER ALCOHOL POLYMERS FOR THE TREATMENT OF CHRONIC PULMONARY INFLAMMATION																			
(57) Abstract																			
<p>A method and medicant for the inhibition of activation of the nuclear transcription NF-<math>\kappa</math>B comprising administering an effective amount of a compound of formula (I) where R = ethylene, R = C<sub>4</sub> to C<sub>14</sub> straight chain or branched alkyl, x is greater than 1, and y = 8 to 18, is provided. The medicant is preferably administered by aerosolization into the mammalian respiratory system. The medicant may also be applied to the mammalian skin. Preferably, the medicant includes a physiologically acceptable carrier which may be selected from buffered saline, isotonic saline, normal saline, petroleum-based ointments and U.S.P. cold cream. There is further provided a method wherein said medicant includes an anti-inflammatory steroid. In addition, a method and medicant for treating cutaneous inflammatory disorders, inhibiting the secretion of the pro-inflammatory cytokines TNF, IL-1, IL-6, IL-8 and the growth factor GM-CSF, is provided.</p>																			
<p>(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>																			
<p>Published Without international search report and to be republished upon receipt of that report.</p>																			
<p style="text-align: center;">    <span style="float: right;">(I)</span> </p>																			
<p style="text-align: center;">  <table border="1"> <caption>Data from Bar Chart</caption> <thead> <tr> <th>Condition</th> <th>2,5 DIHYDROXYBENZOIC ACID (pm/ml x 10<sup>2</sup>)</th> <th>2,3 DIHYDROXYBENZOIC ACID (pm/ml x 10<sup>2</sup>)</th> </tr> </thead> <tbody> <tr> <td>NORMAL SALINE</td> <td>~8.0</td> <td>~6.8</td> </tr> <tr> <td>TYLOXAPOL 0.1mg/ml</td> <td>~4.5</td> <td>~4.5</td> </tr> <tr> <td>TYLOXAPOL 1.0mg/ml</td> <td>~3.5</td> <td>~3.2</td> </tr> <tr> <td>TYLOXAPOL 10.0mg/ml</td> <td>~2.0</td> <td>~2.0</td> </tr> </tbody> </table> </p>					Condition	2,5 DIHYDROXYBENZOIC ACID (pm/ml x 10 <sup>2</sup> )	2,3 DIHYDROXYBENZOIC ACID (pm/ml x 10 <sup>2</sup> )	NORMAL SALINE	~8.0	~6.8	TYLOXAPOL 0.1mg/ml	~4.5	~4.5	TYLOXAPOL 1.0mg/ml	~3.5	~3.2	TYLOXAPOL 10.0mg/ml	~2.0	~2.0
Condition	2,5 DIHYDROXYBENZOIC ACID (pm/ml x 10 <sup>2</sup> )	2,3 DIHYDROXYBENZOIC ACID (pm/ml x 10 <sup>2</sup> )																	
NORMAL SALINE	~8.0	~6.8																	
TYLOXAPOL 0.1mg/ml	~4.5	~4.5																	
TYLOXAPOL 1.0mg/ml	~3.5	~3.2																	
TYLOXAPOL 10.0mg/ml	~2.0	~2.0																	

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Malta	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## USE OF ALKYLARYL POLYETHER ALCOHOL POLYMERS FOR THE TREATMENT OF CHRONIC PULMONARY INFLAMMATION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Continuation-in-Part of U.S. application Serial No. 08/413,699, filed March 30, 1995; which is a Continuation-in-Part of U.S. Patent No. 5,474,760, issued December 12, 1995; which is a Continuation-In-Part of U.S. application Serial No. 299,316, filed August 31, 1994 and now allowed; which is a Continuation-in-Part of U.S. application Serial No. 08/039,732, filed March 30, 1993, now abandoned.

10



BACKGROUND OF THE INVENTIONField of the Invention

The present invention relates to the use of alkylaryl polyether alcohol polymers in the treatment of chronic inflammation. More particularly, the present invention relates to the use of alkylaryl polyether alcohol polymers to reduce the activation of nuclear factor kappa B (NF- $\kappa$ B) and inhibit the secretion of pro-inflammatory cytokines TNF-alpha (TNF- $\alpha$ ), interleukin-1 beta (IL-1 $\beta$ ), interleukin-6 (IL-6), interleukin-8 (IL-8) and the growth factor granulocyte macrophage colony stimulating factor (GM-CSF).

The Prior ArtDiscussion of oxidant-mediated injury.

Oxygen is life-giving to aerobic plants and animals who depend on it for energy metabolism. It can also be lethal to those same organisms when it is altered from its stable dioxygen ( $O_2$ ) state to any one of three partially reduced species: a) the one electron reduced form superoxide anion ( $^{\bullet}O_2$ ); the two electron reduced form hydrogen peroxide ( $H_2O_2$ ); or the deadly three electron reduced form the hydroxyl radical ( $^{\bullet}OH$ ). In biologic systems  $O_2$  and  $H_2O$  are metabolic byproducts of a host of enzymes (oxygenases) that use

oxygen as a cofactor.  $H_2O_2$  is also produced from  $^{\bullet}O_2^-$  by the enzymatic action of superoxide dismutases. However,  $^{\bullet}OH$  is generally produced only when  $^{\bullet}O_2^-$  and  $H_2O_2$  interact with transitional ions of metals such as 5 iron, copper, nickel or vanadium in dangerous cyclical redox reactions:



The above reactions are termed the superoxide-driven 10 Fenton reaction common in biological systems. The Fenton reaction can also be initiated by other reducing substances such as ascorbate in the presence of ferric iron and  $H_2O_2$ .

While  $^{\bullet}O_2^-$  and  $H_2O_2$  are each toxic for 15 biological systems,  $^{\bullet}OH$  (and its alternant hypothesized form the ferryl intermediate  $FeO^{2+}$ ) is a highly reactive species that can oxidize unsaturated membrane lipids, damage cellular proteins and cause mutagenic strand breaks in DNA. To prevent injury from partially 20 reduced  $O_2$  species under normal conditions, cells have evolved an elaborate system of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase) and antioxidant molecules (gluathione, alpha-tocopherol, beta carotene). However, when 25 production of partially reduced  $O_2$  species exceeds capacity of antioxidant defenses to contain them, oxidant injury occurs.

A growing number of mammalian disease 30 entities are now thought to be related to overproduction of partially reduced  $O_2$  species, including the reperfusion injury syndromes myocardial infarction and stroke, adult respiratory distress syndrome, oxygen toxicity of the lung, lung injury from asbestos, Parkinson's disease, thermal and solar burns

-3-

of the skin, injury to the gastrointestinal tract from nonsteroidal anti-inflammatory agents and airway diseases such as chronic bronchitis, asthma and cystic fibrosis (see Table IV, page 60, B. Halliwell and 5 J.M.C. Gutteridge. Methods in Enzymology (1990) 186:1-85). Treatment of these conditions is increasingly directed either toward strategies that prevent enzymatic production of partially reduced O<sub>2</sub> species and to the introduction of exogenous antioxidant compounds 10 that restore oxidant-antioxidant balance in biologic and chemical systems. More recently, as will be outlined below, treatment of inflammation in many of these conditions has been directed toward interrupting activation of the transcription factors mediating the 15 genetic expression of pro-inflammatory cytokines important in the pathogenesis of these conditions.

Discussion of transcription factors and cytokines.

Transcription factors are cellular proteins that bind to regulatory sequences of genes and increase 20 or decrease the rate of gene transcription. By affecting the rate of gene transcription, transcription factors play a critical role in regulation of cell function during health and disease. Among the most important transcription factors in disease are those 25 that regulate expression of the genes for pro-inflammatory cytokines. These cytokines are secreted cellular proteins that dramatically affect the behavior of other cells. As examples, the cytokine TNF- $\alpha$  causes weight loss in patients with tumors or chronic 30 infections, produces cellular death and is thought to be an important mediator of septic shock. The cytokine IL-1 $\beta$  mediates fever, and shares many of the properties of TNF. The cytokine IL-8 (and its close relatives such as RANTES) is a potent chemotactic signal aiding 35 in the recruitment of inflammatory cells such as neutrophils. The cytokine GM-CSF signals the bone

marrow to produce more inflammatory cells, activates those cells once produced and lengthens their survival.

These cytokines play important roles in mediating the pathogenesis of such inflammatory diseases as cystic fibrosis, chronic bronchitis, asthma and viral infections, among many others (T.L. Bonfield, et al. "Inflammatory cytokines in cystic fibrosis lungs". American Journal of Respiratory and Critical Care Medicine (1996) In Press; N.G. McElvaney, et al. "Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor". Journal of Clinical Investigation (1992) 90:1296-1301; K.D. Pfeffer, et al. "Expression and regulation of tumor necrosis factor in macrophages from cystic fibrosis patients". American Journal of Respiratory, Cell and Molecular Biology (1993) 9:511-519; G. Williams and B.P. Giroir. "Regulation of cytokine gene expression: Tumor necrosis factor, interleukin-1, and the emerging biology of cytokine receptors". New Horizons (1995) 3:276-287; C.A. Dinarello. "Role of interleukin-1 and tumor necrosis factor in systemic responses to infection and inflammation". In Inflammation: Basic Principles and Clinical Correlates, second edition. J.I. Gallin, I.M. Goldstein, and R. Snyderman, editors. Raven Press, Ltd., New York (1992) p. 211-232; W.C. Greene. "The interleukins". In Inflammation: Basic Principles and Clinical Correlates, second edition. J.I. Gallin, I.M. Goldstein, and R. Snyderman, editors. Raven Press, Ltd., New York (1992) p. 233-245; M. Baggiolini, et al. "Interleukin-8 and related chemotactic cytokines". In Inflammation: Basic Principles and Clinical Correlates, second edition. J.I. Gallin, I.M. Goldstein, and R. Snyderman, editors. Raven Press, Ltd., New York (1992) p. 247-263; D.W. Golde and G.C. Baldwin. "Myeloid growth factors". In

-5-

5                   Inflammation: Basic Principles and Clinical  
                 Correlates, second edition. J.I. Gallin, I.M.  
                  Goldstein, and R. Snyderman, editors. Raven Press,  
                  Ltd., New York (1992) p. 291-301; R.J. Horwitz and W.W.  
                  Busse. "Inflammation and asthma". Clinics in Chest  
                 Medicine (1995) 16:583-602).

10                  These cytokines share regulation of their  
                  expression by the transcription factor Nuclear Factor  
                  kappa-B (NF- $\kappa$ B), a particularly important transcription  
                  factor mediating inflammatory events (U. Siebenlist, G.  
                  Granzuso and R. Brown. "Structure, regulation and  
                  function of NF- $\kappa$ B". Annual Review of Cell Biology  
                  (1994) 10:405-455). NF- $\kappa$ B is also an important  
                  transcriptional regulator of chemokines such as RANTES  
                  (U. Siebenlist, G. Granzuso and R. Brown. "Structure,  
                  regulation and function of NF- $\kappa$ B". Annual Review of  
                 Cell Biology (1994) 10:405-455) and of inducible nitric  
                  oxide synthase (iNOS) (P.J. Nelson, et al. "Genomic  
                  organisation and transcriptional regulation of the  
                  RANTES chemokine gene". Journal of Immunology (1993)  
                  151:2601-2612), the enzyme producing nitric oxide (NO'),  
                  a critical oxidant chemical produced as part of the  
                  pathogenesis of septic shock. NF- $\kappa$ B is present in the  
                  cytoplasm in an inactive form complexed to an  
                  inhibitory protein I $\kappa$ B. A number of events, yet to be  
                  completely characterized, cause I $\kappa$ B to dissociate from  
                  NF- $\kappa$ B in the cytoplasm. Free NF- $\kappa$ B then localizes to  
                  the nucleus, where it binds to a specific  $\kappa$ B  
                  recognition site in the promoter region of target  
                  genes, prompting their expression. NF- $\kappa$ B is activated  
                  by a number of stimuli, including cytokines themselves,  
                  and by lipopolysaccharide (LPS) (U. Siebenlist, G.  
                  Granzuso and R. Brown. "Structure, regulation and  
                  function of NF- $\kappa$ B". Annual Review of Cell Biology  
                  (1994) 10:405-455). NF- $\kappa$ B is also activated by  
                  oxidants such as hydrogen peroxide (M. Meyer, R.  
                  Schreck, and P.A. Baeverie. " $H_2O_2$  and antioxidants have

opposite effects on the activation of NF- $\kappa$ B and AP-1 in intact cells: AP-1 as secondary antioxidant response factor". EMBO Journal (1993) 12:2005-2015), suggesting that it may be an oxidant-stress responsive

5 transcription factor. Conversely, some of the most potent inhibitors of NF- $\kappa$ B activation are compounds which can also act as antioxidants. A few, but not most, antioxidants prevent activation of NF- $\kappa$ B by LPS, prevent increases in corresponding messenger RNAs for

10 inflammatory cytokines and decrease levels of TNF and IL-1 in the circulation following LPS injection (E.M. Eugui, et al. "Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor  $\alpha$ , IL-1 $\beta$  and IL-6 by human peripheral blood

15 mononuclear cells". International Journal of Immunology (1993) 6:409-422; R. Schreck, et al. "Dithiocarbamates as potent inhibitors of nuclear factor  $\kappa$ B activation in intact cells". Journal of Experimental Medicine (1992) 175:1181-1194). However, the few antioxidants known to

20 inhibit NF- $\kappa$ B activation share no common structural similarity distinguishing them from those antioxidants that fail to prevent activation of NF- $\kappa$ B (see Eugui, above), preventing one skilled in the art from predicting which antioxidant compounds will and which

25 will not favorably reduce NF- $\kappa$ B activation as a strategy of ameliorating inflammatory events in disease.

Another class of compounds known to inhibit NF- $\kappa$ B activation are anti-inflammatory steroids. Steroids act by combining in the cytoplasm with an intracellular protein called the Glucocorticoid Receptor (GR). Previously, the anti-inflammatory action of steroids was thought to occur exclusively as a result of passage of the GR-steroid complex to the nucleus, where the complex attaches to and influences regulatory gene regions called Glucocorticoid Responsive Elements (GREs). However, recently it has

-7-

been shown that a major mechanism of anti-inflammatory steroid activity is inhibition of NF- $\kappa$ B (I.M. Adcock, et al. "Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells". American Journal of Physiology (1995) 268 (Cell Physiology 37):C331-C338). The GR-steroid complex prevents activation of NF- $\kappa$ B by directly interacting with free NF- $\kappa$ B in the cytoplasm, preventing NF- $\kappa$ B from translocating to the nucleus (A. Ray and K.E. Prefontaine. "Physical association and functional antagonism between the p65 subunit of transcription factor NF- $\kappa$ B and the glucocorticoid receptor". Proceedings of the National Academy of Sciences, USA (1994) 91:752-756). However, the GR-steroid complex accomplishes inhibition of NF- $\kappa$ B by mutual repression. By combining with free NF- $\kappa$ B in the cytoplasm, it too is kept from translocating to the nucleus to up-regulate other anti-inflammatory events. Indeed, mutual repression is thought to explain in part the phenomenon of steroid resistance in severe asthmatics. IL-1, IL-6, TNF and other pro-inflammatory cytokines secreted in the airway during an asthma attack increase cellular activation of NF- $\kappa$ B, providing more NF- $\kappa$ B subunits to bind GR-steroid complexes, reducing the amount of GR-steroid complex available to translocate to the nucleus (P.J. Barnes, A.P. Greening and G.K. Crompton. "Glucocorticoid resistance in asthma". American Journal of Respiratory and Critical Care Medicine (1995) 152:S125-S142).

30                    Discussion of alkylaryl polyether alcohol polymers, including tyloxapol.

Antioxidants are compounds that can be easily oxidized to stable chemical forms. They can protect chemical and biologic systems by sacrificing themselves to oxidation in preference to oxidation of critically important chemical and biological molecules. Not all oxidizable compounds can perform antioxidant function.

To successfully protect chemical and biologic systems from oxidants, the antioxidant must have a higher reactivity for the oxidant than the chemical or biologic molecule which it seeks to protect. To 5 protect the desired chemical and biologic system from oxidation, it is also necessary for the antioxidant to partition itself adjacent to the molecule to be protected. As an example, a molecule to be protected within the lipid bilayer of plasma, endosomal or 10 nuclear membranes might be best protected by an antioxidant with, at least in part, a lipophilic structure, so that it is partitioned to or near the lipid portion of the membrane, adjacent to the molecule needing protection from oxidation.

15 We have recently shown that a previously known class of drugs, the alkylaryl polyether alcohol polymers, are potent antioxidants useful in the treatment of mammalian diseases (U.S. Patent 5,474,760 issued December 12, 1995 and U.S. Serial No. 08/039,732 20 filed March 30, 1993 both to Ghio, Kennedy and Piantadosi). Alkylaryl polyether alcohol polymers are used commercially as surface active detergents and wetting agents (U.S. Patent 2,454,541 to Bock and Rainey). The best known of this class is tyloxapol, a 25 polymer of 4-(1,1,3,3-tetramethylbutyl)phenol with formaldehyde and oxirane. However, other compounds in the class, sharing the properties of tyloxapol, are well known in the art (J.W. Cornforth, et al. "Antituberculous effect of certain surface-active 30 polyoxyethylene ethers in mice". Nature (1951) 168:150-153).

35 Tyloxapol is relatively nontoxic and does not hemolyze red blood cells in a thousand times the concentrations at which other detergents are hemolytic (H.N. Glassman. "Hemolytic activity of some nonionic surface-active agents". Science (1950) 111:688-689). Tyloxapol has been used in human pharmacologic

- 9 -

formulations for over 30 years (M.L. Tainter, et al. "Alevaire as a mucolytic agent". New England Journal of Medicine (1955) 253:764-767). For instance, a composition sold by Winthrop Laboratories (a division of Sterling Drug, Inc.) and by Breon Laboratories (subsidiary of Sterling Drug, Inc.) under the trademark ALEVAIRE®, containing 0.125% SUPERINONE® (brand of tyloxapol) in combination with 2% sodium bicarbonate and 5% glycerin, had been marketed for about 30 years for treatment of mucous secretions in patients with diseases and disorders such as chronic bronchitis, croup, pertussis, and poliomyelitis. (See, for example, a product brochure entitled "ALEVAIRE® Detergent Aerosol for Inhalation" (November, 1961) distributed by Breon Laboratories.).

However, in December of 1981, ALEVAIRE® was withdrawn by the Food and Drug Administration for lack of efficacy for treatment of mucous secretions in patients with diseases and disorders such as chronic bronchitis, croup, pertussis, and poliomyelitis because it was found that there was no evidence that the tyloxapol in ALEVAIRE® had any effect on secretions in the lung from diseases such as chronic bronchitis other than that of water in thinning secretions by simple dilution, and that papers in the manufacturer's bibliography were based on clinical impression and did not reflect adequate controls. (See, letter dated May 27, 1994 to Dr. Thomas Kennedy, one of the co-inventors of the present application, from Ms. Carolann W. Hooton, Chief, Freedom of Information Office, Center for Drug Evaluation and Research, Department of Health & Human Services, Public Health Service, Food and Drug Administration, Rockville, Maryland).

Surprisingly, the present inventors have found that alkylaryl polyether alcohol polymers of the class typified by tyloxapol, are potent inhibitors of

the activation of NF- $\kappa$ B, thereby preventing cellular production of pro-inflammatory cytokines.

Synopsis of background discussion.

5 Inflammation in a multitude of diseases is mediated by activation of the transcription factor NF- $\kappa$ B, which in turn causes an increase in cellular production of pro-inflammatory cytokines such as TNF, IL-1, IL-6, IL-8 and the growth factor GM-CSF, and an increase in critical cellular enzymes, such as 10 inducible nitric oxide synthase (iNOS). The current treatment available to prevent activation of NF- $\kappa$ B and subsequent cytokine secretion is anti-inflammatory glucocorticoids. Recently a few, but not most, 15 antioxidants have been found to also inhibit NF- $\kappa$ B.

15 It is theoretically possible to synthesize a multitude of compounds with antioxidant properties. However, there is no predictable structural similarity among the few agents shown to prevent NF- $\kappa$ B activation. Thus, the demonstration that a compound shows 20 antioxidant activity would not, in of itself, predict that the same compound would also inhibit NF- $\kappa$ B activation and secretion of pro-inflammatory cytokines. Also, the factor limiting use of antioxidants as 25 treatments in biologic systems is the inherent toxicity of many antioxidant compound themselves. Likewise, anti-inflammatory cortosteroids are potent inhibitors of NF- $\kappa$ B, but their use as such is severely limited by the well-known side effects of corticosteroids, including glucose intolerance, hypertension, bone 30 resorption, weight gain and cataracts. Thus, it is a major advantage to discover that a class of commonly used and nontoxic ingredients in medicinal 35 pharmacologic preparations are not only potent antioxidants, but also potent inhibitors of NF- $\kappa$ B activation. Not only can such compounds be used as treatments for diseases where antioxidants might be

-11-

predicted to be of value, but they can be used as treatments for NF- $\kappa$ B mediated inflammatory conditions without themselves causing toxicity to biologic systems.

5

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a method to inhibit oxidant chemical reactions caused by partially reduced O<sub>2</sub> species.

10

It is a further object of the present invention to provide a method to protect mammalian tissues against injury from partially reduced O<sub>2</sub> species.

15

It is a further object of the present invention to provide a method and medicament to protect from airway injury by HOCl/OCl, which for convenience, is referred to herein also as HOCl.

20

It is a further object of the present invention to provide a method for inhibiting oxidant chemical reactions caused by partially reduced O<sub>2</sub> species by aerosol treatment with the therapeutic agent.

25

It is a further object of the present invention to provide a method for inhibiting oxidant chemical reactions caused by partially reduced O<sub>2</sub> species by topical application of the therapeutic agent to the skin.

30

It is a further object of the present invention to provide a method and medicament for the inhibition of activation of the transcription factor NF- $\kappa$ B (thus ameliorating the pro-inflammatory cellular events evoked by activating genes controlled by this regulatory cell protein).

35


It is a further object of the present invention to provide a method and medicament for the inhibition of the cytokines TNF, IL-1, IL-6 and IL-8 and the growth factor GM-CSF.

It is a further object of the present invention to provide a method and medicament for preventing steroid resistance in asthma and other diseases by blocking activation of the transcription factor NF- $\kappa$ B, thereby preventing binding and mutual repression of the glucocorticoid receptor complex by active NF- $\kappa$ B present in the cytoplasm.

It is an advantage of the present invention that the therapeutic agent is produced from a toxicologically characterized class of compounds with low toxicologic potential to biologic systems.

In accordance with these objects and the principles of this invention, it has been found that alkylaryl polyether alcohol polymers, such as 15 tyloxapol, are useful as treatment agents for inhibiting activation of the transcription factor NF- $\kappa$ B, and as inhibitors of cellular secretion of the cytokines TNF, IL-1, IL-6 and IL-8 and the growth factor GM-CSF. Administration may be the same as 20 described in U.S. Patent No. 5,474,760.

The present invention provides a medicament for a medicament for the inhibition of injurious effects of partially reduced O<sub>2</sub> species in chemical and biologic systems comprising as a treatment an effective 25 amount of alkylaryl polyether alcohol polymer of the formula:



-13-

where R = ethylene, R' = C<sub>4</sub> to C<sub>14</sub> straight or branched alkyl, x is greater than 1, and y = 2 to 18, effective to inhibit oxidant chemical reactions caused by the oxidant species in the mammal, thereby treating the  
5 mammalian disease entities.

Also, the alkylaryl polyether alcohol polymer is thought effective by virtue of having a hydrophobic portion of structure placing it in lipid membranes, and also a hydrophilic portion of structure allowing it to  
10 interact with the external environment or cytosolic compartment of the cell.

Also, the present invention provides a method and medicament comprising administering to a mammal a treatment effect among of tyloxapol and related  
15 alkylaryl polyether alcohol polymers.

In one embodiment of the invention, the medicament is directly instilled into the respiratory system and administered by aerosolization. In this embodiment, the medicament preferably includes a  
20 physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, isotonic saline, and normal saline and an additional treatment effective amount of cetyl alcohol. The pH of the alkylaryl polyether alcohol  
25 polymer and carrier mixture is preferably greater than 6.5 but equal to or less than 7.4.

In other embodiments of the invention, this medicament is applied topically to the skin. In this embodiment, the medicament preferably includes a  
30 physiologic carrier selected from a commercially available petrolatum based ointment or U.S.P. cold cream.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Reference to the following detailed  
35 description may help to better explain the invention in conjunction with the drawings which:

Figure 1 shows a graph of the inhibitory effect of tyloxapol on  $^{\bullet}\text{OH}$  generation by the Fenton reaction, as measured by hydroxylation of salicylate;

5 Figure 2 shows a graph of the inhibitory effect of tyloxapol on  $^{\bullet}\text{OH}$  generation by the Fenton reaction, as measured by oxidation of the sugar, 2-deoxyribose;

10 Figure 3 shows lung wet/dry weight ratios in rats exposed to 100% oxygen and treated with normal saline, tyloxapol, and tyloxapol plus cetyl alcohol;

Figure 4 shows pleural fluid accumulation in rats exposed to 100% oxygen and treated with normal saline, tyloxapol, and tyloxapol plus cetyl alcohol;

15 Figure 5A shows the effect of tyloxapol on HOCl-mediated lung injury in rats as shown by an increase in protein concentration;

Figure 5B shows the effect of tyloxapol on HOCl-mediated lung injury in rats as shown by an increase in % neutrophils;

20 Figure 6 shows activation of the transcription factor NF- $\kappa$ B by IL-1 and  $\text{H}_2\text{O}_2$  and inhibition of this activation by tyloxapol;

25 Figure 7 shows baseline secretion of IL-8 by unstimulated human monocytes with and without tyloxapol treatment;

Figure 8A shows human monocyte secretion of TNF- $\alpha$  with and without tyloxapol treatment;

Figure 8B shows human monocyte secretion of IL-1 $\beta$  with and without tyloxapol treatment;

30 Figure 8C shows human monocyte secretion of IL-6 with and without tyloxapol treatment;


Figure 8D shows human monocyte secretion of IL-8 with and without tyloxapol treatment; and

35 Figure 8E shows human monocyte secretion of GM-CSF with and without tyloxapol treatment.

#### DETAILED DESCRIPTION OF THE INVENTION

-15-

Alkylaryl polyether alcohol polymers can in general be synthesized by condensing alkylaryl alcohols with formaldehyde, as described in U.S. Patent 2,454,541, the disclosure of which is incorporated herein by reference. The present invention provides a medicament for the inhibition of injurious effects of partially reduced  $O_2$  species in chemical and biologic systems comprising as a treatment an effective amount of alkylaryl polyether alcohol polymer of the formula:



where  $R$  = ethylene,  $R'$  =  $C_4$  to  $C_{14}$  straight or branched alkyl,  $x$  is greater than 1, and  $y$  = 2 to 18, effective to inhibit oxidant chemical reactions caused by the oxidant species in the mammal, thereby treating the mammalian disease entities. All alkylaryl polyether alcohol polymers disclosed in this patent should work in the present invention. Several specific alkylaryl polyether alcohol polymers can be synthesized by methods previously described (J.W. Cornforth, et al. "Antituberculous effect of certain surface-active polyoxyethylene ethers in mice". Nature (1951) 168:150-153). The prototype compound of this class, tyloxapol, can be conveniently purchased in pharmacologically acceptable purity from Nycomed, Inc., 33 Riverside Ave., Rensselaer, NY 12144.

Treatment of patients for inhibition of the activation of transcription factor NF- $\kappa$ B and production of the cytokines TNF- $\alpha$ , IL-1 $\beta$ , IL-6, IL-8 and the

growth factor GM-CSF with alkylaryl polyether alcohol polymers, particularly tyloxapol, is essentially the same as the administration described in U.S. Patent No. 5,474,760 and U.S. Serial No. 08/039,732. More 5 specifically, for treatment of mammalian respiratory conditions related to an overproduction of partially reduced O<sub>2</sub> species, and for inhibition of the activation of transcription factor NF- $\kappa$ B and production of the cytokines TNF- $\alpha$ , IL-1 $\beta$ , IL-6, IL-8 and the growth 10 factor GM-CSF, the alkylaryl polyether alcohol polymer is dissolved in sterile 0.9% NaCl for injection, and the pH is adjusted to approximately 7.0 by addition of NaOH or HCl. A nonpolymeric alkyl or aryl alcohol such as cetyl alcohol (hexadecanol) may be added equivalent 15 to 1 to 1.5 times the weight of tyloxapol to increase the effectiveness of the mixture in protection against oxidant injury.

This mixture is then administered to the lung by direct instillation into the respiratory system. 20 The mixture may also be administered by aerosolization using a clinically available positive pressure driven nebulizer that produces respirable particles of less than 5 microns mass median diameter.

As an example, a 0.125 to 0.5% solution of 25 tyloxapol is made in sterile 0.9% NaCl and double glass distilled deionized water to make it isotonic with respect to respiratory secretions. The pH is adjusted to approximately 7.0 to prevent bronchospasm from extremes of acidity or alkalinity. This mixture is 30 sterilized by vacuum filtration through a 0.22 micron Millipore filter and 3.3 ml each is packaged into 5 ml unit dose glass vials with rubber stoppers fastened with aluminum crimp-on "flip-tear" seals. To provide additional sterilization of product, unit dose vials 35 are terminally autoclaved 12-14 minutes at 125° C. A 0.5% concentration of glycerol may be optionally added

-17-

to the above mixture to stabilize droplet size during aerosolization.

To enhance the effectiveness of the therapy, a treatment effective amount of a commonly available 5 anti-inflammatory steroids, such as methylprednisolone (1-5 mg), triamcinolone (1-5 mg), beclomethasone dipropionate (1-4 mg), flunisolide (200-400  $\mu$ g) or dexamethasone (200-400  $\mu$ g, either as dexamethasone or 10 its water soluble congener dexamethasone sodium phosphate) may be added to the formulation. The amount of tyloxapol to steroid to be effective will vary depending upon which steroid is used. For example, a ratio of 5 mg. tyloxapol to 25 mg. of 15 methylprednisolone, 5 mg of tyloxapol to 25 mg. of triamcinolone, 6 mg. of tyloxapol to 25 mg. of beclomethasone dipropionate, 125 mg. of tyloxapol to 250 mg. of flunisolide, or 125 mg. tyloxapol to 250 mg. of dexamethasone, either as dexamethasone are 20 preferred. Combining an alkylaryl polyether alcohol polymer and an anti-inflammatory steroid provides a means for reducing steroid resistance in asthma and other diseases, thereby enhancing steroid effectiveness. This is accomplished by blocking, with 25 addition of the alkylaryl polyether alcohol polymer, activation of the transcription factor NF- $\kappa$ B, thereby preventing binding and thereby mutual repression of the steroids receptor complex by active NF- $\kappa$ B present in the cytoplasm. An additional advantage of the combined 30 formulation is that alkylaryl polyether alcohol polymers, as surface active agents, will aid in the solubilization of water-insoluble anti-inflammatory steroids such as triamcinolone, beclomethasone dipropionate, flunisolide or dexamethasone, thereby 35 promoting their effective distribution to the airway.

For administration of treatment effective doses to the lungs and bronchial airways, 3 ml of sterile tyloxapol solution is inhaled as an aerosol

every 4 to 12 hours using a clinically available positive pressure driven nebulizer (Acorn or deVilbiss). Alternately, the mixture can be nebulized into the respiratory delivery circuit of a mechanical ventilatory. A beta sympathetic agonist bronchodilator (such as 1.25 to 2.5 mg of albuterol) can be mixed with the tyloxapol solution and nebulized concomitantly to prevent any transient bronchospasm that might occur from the tyloxapol or tyloxapol-steroid solution itself. A quaternary ammonium derivative of atropine such as ipratropium (500  $\mu$ g) or glycopyrrolate (200-1,000  $\mu$ g) can also be added to the tyloxapol solution as a bronchodilator for the same purpose.

For administration of treatment effective doses to the nasal airway, the sterile tyloxapol solution or tyloxapol solution containing the above anti-inflammatory steroid is placed in a commercially available 10 ml squeeze bottle or similar device that generates a fine mist. For relief of nasal rhinitis, rhinosinusitis or other inflammation, 1 to 4 sprays from this dispense is inhaled into each nostril 2 to 4 times a day.

For treatment of cutaneous inflammatory disorders such as solar burn, psoriasis or other dermatoses, a 0.5 to 5% mixture (w/w) is made with an alkylaryl polyether alcohol such as tyloxapol, or tyloxapol and an anti-inflammatory steroid such as hydrocortisone, triamcinolone or flunisolide, in a commercially available petrolatum based ointment such as Aquaphor (Beiersdord, Inc., Norwalk, CT), white petrolatum or U.S.P. cold cream as the base vehicle. This mixture is rubbed lightly onto the affected skin area 3 to 4 times daily.

In order to facilitate a further understanding of the invention, the following examples primarily illustrate certain more specific details thereof.

-19-

Example I demonstrates the potent activity of alkylaryl polyether alcohol polymers as 'OH scavengers in chemical systems. Example II demonstrates the therapeutic benefit of using alkylaryl polyether 5 alcohol polymers to prevent mammalian lung injury from exposure to 100% oxygen. Example III demonstrates the potent activity of alkylaryl polyether alcohol polymers as scavengers of HOCl in chemical systems. Example IV demonstrates inhibition of activation of the 10 transcription factor NF- $\kappa$ B. Example V demonstrates suppression of cytokine and GM-CSF production.

EXAMPLE I

Inhibition of Oxidants Generated by the Fenton Reaction.

15 The first chemical system used to test the antioxidant activity of alkylaryl polyether alcohol polymers employed salicylate as the target molecule of oxidants. The hydroxyl radical reacts with salicylic acid (2 hydroxybenzoic acid) to produce two 20 dihydroxybenzoic acid products, 2,3- and 2,5-dihydroxybenzoic acid. These hydroxylated products provide evidence of 'OH generation (R.A. Floyd et al. Journal of Biochemical and Biophysical Methods (1984) 10:221-235; R.A. Floyd et al. Journal of Free Radicals in Biology & Medicine (1986) 2:13-18).

25 The detection of 2,3- and 2,5-dihydroxybenzoic acid was performed using high performance liquid chromatography with electrochemical detection. Suspensions of 10  $\mu$ M FeCl<sub>3</sub>, 1 mM H<sub>2</sub>O<sub>2</sub>, 1.0 30 mM ascorbate and 10.0  $\mu$ M salicylic acid were employed to generate and detect 'OH. Either 1.0 ml of normal saline or tyloxapol (final concentrations of 0.0 to 10 mg/ml) were added. The reaction mixtures were 35 incubated at 45°C for 30 min and centrifuged at 1200 g for 10 min. Supernatant was centrifuged (Beckman Microfuge E) through a 0.22  $\mu$ M microfuge tube filter (PGC Scientific No. 352-118) at 15,000 g.

-20-

A 100  $\mu$ L sample of the eluate was injected onto a C18 RP HPLC column (250 x 4.7 mm, Beckman No. 235329). Hydroxylated products of salicylate were quantified with a Coulchem electrochemical detector (ESA model 5100 A) with the detector set at a reducing potential of -0.40 VDC. The guard cell (used as a screen) was set at an oxidizing potential of +0.40 VDC. Measurements were done in duplicate. Figure 1 shows that the addition of tyloxapol to the reaction mixture inhibited  $\cdot$ OH generation in a concentration dependent manner.

The second chemical system used to test the antioxidant activity of alkylaryl polyether alcohol polymers employed 2-deoxyribose as the target molecule of oxidants. This pentose sugar reacts with oxidants to yield a mixture of products. On heating with thiobarbituric acid (TBA) at low pH, these products form a pink chromophore that can be measured by its absorbance at 532 nm (B. Halliwell and J.M.C. Gutteridge. Methods in Enzymology (1990) 186:1-85).

The chemical system employed to generate oxidants was a reaction mixture containing 10.0  $\mu$ M FeCl<sub>3</sub>, 1.0 mM ascorbate, 1.0 mM H<sub>2</sub>O<sub>2</sub> and 1.0 mM deoxyribose in Hanks Balanced Salt Solution. This system is useful for measuring site-specific  $\cdot$ OH generation on biologic molecules, as described by Halliwell and Gutteridge in the reference immediately above. Either 0.1 ml of normal saline or tyloxapol (final concentrations of 0.0 to 10.0 mg/mg) were added.

The reaction mixtures were incubated at 45°C for 30 min and centrifuged at 1200 g for 10 min. One ml of both 1.0% (w/v) TBA and 2.8% (w/v) trichloroacetic acid were added to 1.0 ml of supernatant, heated at 100°C for 10 min, cooled in ice, and the chromophore determined in triplicate by its absorbance at 532 nm. Figure 2 shows that the addition of 10 mg/ml tyloxapol to the reaction mixture causes

-21-

marked inhibition of the oxidation of deoxyribose, as measured by absorbance of the oxidant reaction produced at 532 nm.

5 The third system used to test the antioxidant activity of alkylaryl polyether alcohol polymers employed asbestos as the source of iron for oxidant generation and 2-deoxyribose as the target molecule of oxidants. The generation of oxidants by asbestos has been described previously (A.J. Ghio et al. American  
10 Journal of Physiology (Lung Cellular and Molecular  
Physiology 7) (1992) 263:L511-L518). The reaction mixture, in a total volume of 2.0 ml phosphate-buffered saline (PBS) contained the following reagents: 1.0 mM deoxyribose, 1.0 mM H<sub>2</sub>O<sub>2</sub>, 1.0 mM ascorbate, and 110  
15 mg/ml crocidolite asbestos. The mixture was incubated at 37°C for 1 hour with agitation and then centrifuged at 1,200 g for 10 min.

Oxidant generation was assessed by measuring TBA reactive products of deoxyribose as detailed in the  
20 paragraph above. Measurements were done in triplicate. TABLE I below shows that the addition of tyloxapol inhibited in a concentration dependent manner the generation of oxidants by asbestos, as measured by absorbance of the oxidant reaction product at 532 nm.

25

TABLE I

30

## Effect of Tyloxapol on Oxidant Generation of Asbestos

Absorbance at 532 nm

Tyloxapol 0.0 mg/ml	0.93 ± 0.02
Tyloxapol 0.1 mg/ml	0.89 ± 0.04
Tyloxapol 1.0 mg/ml	0.75 ± 0.01
Tyloxapol 10.0 mg/ml	0.53 ± 0.04

EXAMPLE IIProtection from Mammalian Lung Injury by 100% Oxygen.

To determine if alkylaryl polyether alcohol polymers could protect against oxidant injury to intact biologic systems, this treatment was studied in a well established model of oxygen toxicity to the lung (J.F. Turrens, et al. Journal of Clinical Investigation (1984) 73:87-95). Sixty-day old male Sprague-Dawley rats (Charles River, Inc., Wilmington, MA) were tracheally instilled with 0.5 ml of either normal saline, tyloxapol (6.0 mg) or tyloxapol (6.0 mg) and cetyl alcohol (hexadecanol, 11.0 mg). These rats (n=10 in each treatment group) were then exposed to either air or 100% oxygen in plexiglass chambers at a flow rate of 10 liters/min.

Oxygen percentage was monitored by a polarographic electrode and maintained continuously above 98%. Temperature was maintained between 20 and 22°C. Survival times were determined by checking animals every 4 hours. Separate groups of rats treated similarly (n=10 in each treatment group) were exposed to 100% oxygen for 61 hours, and then were euthanized with 100 mg/kg intraperitoneal pentobarbital. Pleural fluid volume was measured by aspirating pleural fluid from the chest cavity through a small incision in the diaphragm. Lung wet/dry weight ratios were calculated from the left lung after drying the tissue for 96 hours at 60°C. Survival data is shown in TABLE II below.

Rats receiving intratracheal tyloxapol had markedly improved survival compared to placebo control animals instilled with saline. The protective effect of tyloxapol was further enhanced by combining it with cetyl alcohol.

TABLE II			
Effect of Tyloxapol on Oxygen Toxicity in Rats			
Percent Survival			
Hours	Saline	Tyloxapol	Tyloxapol/ Cetyl Alcohol
5	100	100	1
	100	100	100
	83	100	100
	42	100	100
	17	75	100
10	17	75	100
	8	58	100
	8	58	100
	8	58	100
	0	58	100
15	0	58	100

Lung wet/dry weight ratios were substantially lower in rats treated with tyloxapol or tyloxapol and cetyl alcohol (Figure 3), demonstrating that tyloxapol or the combination of tyloxapol and cetyl alcohol protect against edema formation from oxidant injury.

Rats treated with tyloxapol or the combination of tyloxapol and cetyl alcohol also had less pleural fluid accumulation than saline treated controls (Figure 4).

These results demonstrate the ability of alkylaryl polyether alcohol polymers such as tyloxapol to protect against oxidant tissue injury. The survival studies (TABLE II) further demonstrate that the protective effect of the medicament is enhanced by combining it with alcohols such as cetyl alcohol.

EXAMPLE III  
Scavenging of HOCl.

5 The activity of tyloxapol to scavenge OCl<sup>1</sup> was tested by studying its ability to prevent OCl<sup>1</sup> mediated oxidant conversion of diethanolamine to its corresponding stable chloramine ("Determination of HOCl Production by Myeloperoxidase", Robert A. Greenwald, editor, Handbook of Methods for Oxygen Radical Research, CRC Press, Boca Raton, Florida (1987), page 300).

10 The reaction mixture comprised 0.9 ml of 10.0 mM diethanolamine in 0.1 N sodium acetate buffer, pH 4.5. To this was added either 100  $\mu$ L of 0.1 M NaCl or tyloxapol in 0.1 M NaCl, and the baseline absorbance was read at 280 nm. NaOCl was added to a final concentration of 10 mM.

15 The reaction mixture was incubated 15 minutes, and the absorbance was measured at 280 nm. The difference in  $A_{280}$  before and after addition of NaOCl was used as a measure of concentration of the stable chloramine. Experiments were performed in 20 triplicate. Results are summarized in Table III below:

TABLE III	
Microliters of Tyloxapol (10 mg/ml)	Absorbance (mean $\pm$ SD)
0	0.505 $\pm$ 0.002
25	0.468 $\pm$ 0.008
50	0.444 $\pm$ 0.023
75	0.377 $\pm$ 0.010
100	0.319 $\pm$ 0.025

30 To demonstrate that tyloxapol is also an effective scavenger of HOCl in vivo, the ability of tyloxapol to protect against lung injury from HOCl was studied in 60-day old male Sprague-Dawley rats (n=6 per treatment group) weighing 250-300 g (Charles River Breeding Labs, Wilmington, MA). After anesthesia with 35 halothane (2-5%) rats were injected intratracheally

-25-

with either 0.3 ml of 2.0 mM NaOCl in normal saline (buffered to pH 6.0), or with normal saline alone. The rats were allowed to recover, and one hour later were dosed intratracheally with either 6.0 mg tyloxapol in 5 normal saline or with normal saline. Twenty-four hours after NaOCl instillation, all rats were euthanized with sodium pentobarbital. The tracheas were cannulated and lungs were lavaged with normal saline (35 ml/kg body weight). After staining of the lavage fluid with a 10 modified Wright's stain (Diff-Quick stain, ASP, McGraw Park, IL), the cell differentials were determined on 500 cells/sample. Values were expressed as the percentage of total cells recovered. Lavage protein was measured using the Bio-Rad method for total protein 15 determination as modified for use on the centrifugal analyzer.

Intratracheal instillation of NaOCl caused acute lung injury as demonstrated by a marked increase 20 in protein concentration (Figure 5A) and % neutrophils (% PMNs) (Figure 5B) in lung lavage fluid. Post exposure treatment with tyloxapol significantly reduced lavage protein concentration ( $p < 0.001$ ) and % PMNs ( $p < 0.01$ ), demonstrating that tyloxapol also protects against HOCl-mediated cytotoxicity *in vivo*.

25 Thus, tyloxapol is a potent inhibitor of the oxidant activity of HOCl, and should be useful in preventing HOCl mediated oxidant injury of the airway. Administration of tyloxapol by tracheal instillation to patients with neutrophil-mediated airways diseases such 30 as cystic fibrosis and chronic bronchitis should inhibit HOCl produced in these patients and therefore protect them from oxidant injury. The result should be even better if some cetyl alcohol is admixed with the tyloxapol; preferably, the cetyl alcohol is added in 1 35 to 1.5 times the weight of the tyloxapol.

Preparation of samples for administration to the patient should be the same as described above, most

preferably inhalation of 3 ml to a 0.125 to 0.5% solution of tyloxapol by jet aerosol every 4 to 12 hours.

EXAMPLE IV

5 Inhibition of the Activation of  
Transcription Factor NF- $\kappa$ B by Tyloxapol.

Control of genetic expression of cell proteins is controlled by proteins called transcription factors which bind to regulatory DNA sequences and influence production of the protein product of the regulated gene. An important transcription factor for inflammation is NF- $\kappa$ B, which promotes transcription of the messenger RNA for pro-inflammatory cytokines and growth factors.

To determine if tyloxapol inhibits activation of the transcription factor NF- $\kappa$ B, tyloxapol was tested in electrophoretic mobility gel shift assays performed on cultured A549 human lung epithelial cells. A549 human pulmonary epithelial cells were cultured in Ham's F-12 medium supplemented with 10% heat-inactivated fetal calf serum, L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100  $\mu$ g/ml) and amphotericin B (250  $\mu$ g/ml). Confluent cells were stimulated with 10 U/ml IL-1 $\beta$  or 100  $\mu$ M H<sub>2</sub>O<sub>2</sub>. In some cultures 100  $\mu$ g/ml tyloxapol was added at the same time as the stimulators. After 2 hours of incubation, nuclear extracts were isolated as described by Dignam et al. (J.D. Dignam, R.M. Lebovita, and R.G. Roeder. "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei" Nucleic Acid Research (1983) 11:1475-1489), with minor modifications (C.V. Gunther and B.J. Graves "Identification of ETS domain proteins in murine T lymphocytes that interact with the Moloney murine leukemia virus enhancer" Molecular and Cellular Biology (1994) 14:7569-7580). In brief, after removal of the supernatant, cells were scraped gently in 20-30 ml of

-27-

PBS containing 1 mM phenylmethylsulfonyl fluoride (PMSF) and 1 mM dithiothreitol (DTT). The cell suspension were centrifuged and the pellets were resuspended and incubated for 15 min in 1 ml buffer A containing 10 mM HEPES, 1.5 mM MgCl<sub>2</sub>, 10 mM KCl, 1 mM PMSF, 1 mM DTT, 10 mM  $\beta$ -glycerolphosphate, 2.5 mM benzamidine, 1 mM NaF, 1 mM NaVO<sub>4</sub>, 1 mg/ml leupeptin and 1 mg/ml pepstatin A, then were sheared by 5 times passage of the suspensions through a 25 G needle.

10 After centrifugation, the pellets were suspended and stirred for 30 min in buffer C containing 25% vol/vol glycerol, 0.25 M NaCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM ethylenediamine tetraacetic acid (EDTA), 1 mM PMSF, 1 mM DTT, 10 mM  $\beta$ -glycerolphosphate, 2.5 mM benzamidine, 1 mM NaF, 1 mM NaVO<sub>4</sub>, 1 mg/ml leupeptin and 1 mg/ml pepstatin A. After centrifugation, nuclear extracts were obtained by dialysis of the supernatants in buffer D containing 20 mM HEPES, 20% vol/vol glycerol, 100 mM KCl, 0.2 mM EDTA, 1 mM PMSF and 1 mM DTT. Utilizing the wild type consensus sequences for AP-1 (W. Lee, P. Mitchell and R. Tijan "Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements" Cell (1987) 49:742-752) and NF- $\kappa$  B (R. Sen and D. Baltimore. "Multiple nuclear factors interact with the immunoglobulin enhancer sequences" Cell (1986) 46:705-716) loci, the following oligonucleotides were synthesized (binding sites underlined):

AP-1: 5' - TTCCGGCTGACTCATCAAGCG-3'

3' -AAGGCCGACTGAGTAGTTCGC-5'

30 NF- $\kappa$ B: 5' -AGTTGAGGGGACTTTCCCAGGC-3'

3' -TCAACTCCCCTGAAAGGGTCCG-5'

The oligonucleotides were purified by denaturing polyacrylamide gel electrophoresis followed by passage over Sep-Pak C18 columns. Each complementary strand was end-labeled by phosphorylation with [ $\gamma^{32}\text{P}$ ]-ATP and T4 polynucleotide kinase. Double-stranded DNA probes were generated by annealing the complementary end-labeled oligonucleotide strands, boiling for 3 min and slow-cooling to room temperature in a water bath. Unincorporated radionucleotides were removed by Sephadex G-25 column chromatography. Binding reactions were performed for 20 min on ice with 5-10  $\mu\text{g}$  total protein in a 20  $\mu\text{L}$  volume containing 300 ng bovine serum albumin (BSA), 1-2  $\mu\text{g}$  poly(dI-dC), 50 mM DTT, 0.5 mM PMSF and 1-2  $\times 10^4$  c.p.m. of  $^{32}\text{P}$ -labeled probes. In addition, a concentration of 6 mM MgCl<sub>2</sub> was used for AP-1 binding reactions. In selected samples a 100-fold molar excess of unlabeled DNA probe was included in the binding reaction in order to confirm the specificity of DNA-protein interactions. DNA-protein complexes were separated from unbound DNA probe on 4.5% polyacrylamide gels under high ionic strength conditions in 50 mM (hydroxymethyl) aminomethane (Tris), 0.4 M glycine, 2 mM EDTA and 2.5% vol/vol glycerol, pH 8.5. Electrophoresis was carried out at 4°C at a constant current of 20 mA. Gels were dried under vacuum and exposed to film at -70°C for 6-24 hours with an intensifier screen.

As shown in Figure 6, tyloxapol prevents IL-1 $\beta$  or H<sub>2</sub>O<sub>2</sub> induced binding of NF- $\kappa$ B, but not AP-1, to nuclear extracts. Confluent A549 human pulmonary epithelial cells were incubated without (lane 1) or with 10 U/ml of IL-1 $\beta$  (lanes 2 and 3) or 100  $\mu\text{M}$  H<sub>2</sub>O<sub>2</sub> (lanes 4 and 5). Tyloxapol (100  $\mu\text{g}/\text{ml}$ , lanes 3 and 5) was added at the same time as stimulators. After 3 hours of incubation, nuclear extracts were prepared. Aliquots of the extracts were incubated with  $^{32}\text{P}$ -labeled NF- $\kappa$ B- and AP-1-specific oligonucleotides and analyzed

-29-

in electrophoretic mobility shift assays as detailed above. Position of the specific DNA-protein complexes are indicated by the arrowhead. One hundred-fold molar excess of the appropriate unlabeled DNA probe was 5 included in the binding reactions for the samples shown in the competition lanes.

Thus, tyloxapol inhibits activation of the transcription factor NF- $\kappa$ B. This action is specific, since the activation of another important transcription 10 factor, AP-1, was not affected. Blocking activation of NF- $\kappa$ B would carry the advantage of reducing cell production of pro-inflammatory cytokines and growth factors, thereby ameliorating inflammation in the tissue treated.

15

#### EXAMPLE V

##### Suppression of Cytokine Production by Tyloxapol.

Inhibiting activation of the transcription factor NF- $\kappa$ B would be expected to reduce secretion of the pro-inflammatory cytokines influenced by NF- $\kappa$ B. As 20 examples, cachexia and/or anorexia prominent in patients with severe cystic fibrosis lung disease is caused by an increased rate of TNF gene transcription and secretion by cystic fibrosis macrophages. (See K.D. Pfeffer, et al. "Expression and regulation of tumor 25 necrosis factor in macrophages from cystic fibrosis patients". American Journal of Respiratory, Cell and Molecular Biology. (1993) 9:511-519). TNF is also an important mediator in the pathogenesis of asthma (R.J. Horwitz and W.W. Busse. "Inflammation and asthma". 30 Clinics in Chest Medicine (1995) 16:585-602). Tyloxapol should ameliorate the adverse effects of TNF in cystic fibrosis and asthmatic pathophysiology when administered to cystic fibrosis or asthmatic patients because, as shown below, it is a potent suppressant of 35 TNF secretion by monocyte-macrophage cell lines. By inhibiting TNF secretion, tyloxapol should also lessen

the corticosteroid resistance in asthma caused in part by this cytokine (P.J. Barnes, et al. "Glucocorticoid resistance in asthma". American Journal of Respiratory and Critical Care Medicine (1995) 152:S125-S142).

5 Also, IL-8 is a potent chemoattractant for polymorphonuclear neutrophils, and plays a prominent role in the pathogenesis of diverse diseases such as cystic fibrosis, chronic bronchitis, Adult Respiratory Distress Syndrome, and psoriasis (See, H. Nakamura, et al, "Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line". Journal of Clinical Investigation (1992) 89:1478-1484; N.G. McElvaney, et al. "Modulation of airway inflammation in cystic fibrosis". In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. Journal of Clinical Investigation (1992) 90:1296-20 1301; M. Baggiolini, et al. "Interleukin-8 and related chemotactic cytokines". In Inflammation: Basic Principles and Clinical Correlates, second edition. J.I. Gallin, I.M. Goldstein, and R. Snyderman, editors. Raven Press, Ltd., New York (1992) p. 247-263). By 25 inhibiting IL-8 secretion, tyloxapol should ameliorate the influx of neutrophils into inflamed tissue in these diseases. Finally, GM-CSF is an important growth factor activating and lengthening the life-span of eosinophils in asthma (D.W. Golde and G.C. Baldwin. 30 "Myeloid growth factors". In Inflammation: Basic Principles and Clinical Correlates, second edition. J.I. Gallin, I.M. Goldstein, and R. Snyderman, editors. Raven Press, Ltd., New York (1992) p. 291-301; R.J. Horwitz and W.W. Busse. "Inflammation and asthma". 35 Clinics in Chest Medicine (1995) 16:583-602). By reducing GM-CSF secretion, tyloxapol should help reduce

-31-

the eosinophilia and its consequences for the asthmatic airway.

To test the effect of tyloxapol on cytokine secretion, monocytes were prepared by centrifugal elutriation from leukopaks obtained from healthy human donors. Purified monocytes were suspended at  $2 \times 10^6$  cells in RPMI-1640 supplemented with 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, 1% MEM non-essential amino acids, 10 25 mM N-2-hydroxyethyl-ierazine-N' -ethane sulfonic acid (HEPES) and 196 Nutridoma (Boehringer Mannheim, Indianapolis, IN), and 5% pooled, heat-inactivated human AB serum (Pel-freeze, Brown Deer, WI).

One-half ml of this cell suspension was added 15 to each well of a 48-well flat bottomed tissue culture plate. Test materials (diluted in complete medium at 4X the desired final concentration) were added in 250  $\mu$ L volumes to each well. Control wells received 250  $\mu$ L of either complete medium or 250  $\mu$ L of IL-4 (diluted to 20 4X the desired final concentration of 50  $\mu$ g/ml).

Tyloxapol was tested in triplicate at four 25 concentrations in either the presence or absence of 100 ng/ml *Salmonella typhosa* lipopolysaccharide (LPS, 250  $\mu$ L of 4X desired final concentration added) and incubated at 37°C in humidified 5% CO<sub>2</sub> for 16 hours. At this time culture supernatants were aspirated off and the unattached cells and cell debris were removed by filtration. The release of TNF- $\alpha$ , IL-1 $\beta$ , IL-6 and IL-8 30 and the growth factor GM-CSF was determined in the cell-free supernatants using ELISA capture assays. The concentration of endotoxin in all buffers and tyloxapol was below the level of detection (25 pg/ml).

Incubations of monocytes in concentrations of tyloxapol 35 equal to or below 100  $\mu$ g/ml were associated with no significant elevations in LDH concentration in the supernatant, supporting a lack of cytotoxicity by tyloxapol, and suggesting that the inhibition of

cytokine secretion noted below was not due to an injurious detergent effect on monocytes.

Tyloxapol had no effect on baseline release of any mediator except for IL-8, but significantly decreased secretion of IL-8 in unstimulated cells (Figure 7). However, release of several mediators by LPS stimulated monocytes was significantly diminished at low concentrations of tyloxapol. Secretion of TNF- $\alpha$ , IL-1 $\beta$ , IL-6, IL-8 and GM-CSF was significantly ( $p < 0.01$ ) decreased by tyloxapol in a dose-dependent manner (Figures 8A-8E), with effective concentrations for 50% inhibition ( $EC_{50}$ ) ranging from 30-70  $\mu$ g/ml (Table IV, below). However, tyloxapol did not change PAF release from LPS stimulated monocytes, providing additional evidence that the effect of tyloxapol was selective on cytokines influenced by NF- $\kappa$ B.

TABLE IV	
Effective Concentrations of Tyloxapol for 50% Inhibition $EC_{50}$ of Monocyte Cytokine Release	
Cytokine	$EC_{50}$ ( $\mu$ g/ml)
TNF- $\alpha$	30
IL-1 $\beta$	60
IL-6	30
IL-8	70

Thus, tyloxapol is a potent inhibitor of pro-inflammatory cytokine secretion, a result expected of a therapeutic agent that inhibits the transcription factor NF- $\kappa$ B. As such, tyloxapol would be expected to help ameliorate cachexia and/or anorexia from TNF, such as in patients with cystic fibrosis.

Aerosolized tyloxapol would also be expected to reduce airway injury of diseases of airway, such as cystic fibrosis, asthma and chronic bronchitis, and diffuse lung inflammation and injury, such as in Adult Respiratory Distress Syndrome, by inhibiting local

-33-


production of the chemoattractant IL-8, TNF, IL-1, IL-6 and GM-CSF. Topical tyloxapol would be expected to ameliorate inflammatory diseases of the skin such as psoriasis and response to solar or thermal burn by 5 reducing local production of the same cytokines. The result should be even better if the tyloxapol is mixed in a formulation with glucocorticoids, since by inhibiting NF- $\kappa$ B by a different mechanism than does the glucocorticoid-GR receptor complex, tyloxapol would 10 reduce cytokine-induced-NF- $\kappa$ B related resistance to anti-inflammatory glucocorticoids, as discussed above. Reduction in steroid resistance would, in turn, potentiate the overall anti-inflammatory activity of glucocorticoids and enhance amelioration of 15 inflammation of the body compartment treated.

Tyloxapol should also work even better if admixed with some cetyl alcohol, added in 1 to 1.5 times the weight of tyloxapol. Preparation of the samples for administration to the patient should be the same as 20 described above, most preferably inhalation of 3 ml of a 0.5% solution of tyloxapol, with or without admixed anti-inflammatory glucocorticoid by jet aerosol every 4 to 12 hours, or topical application of a 0/5 to 5% (w/w) application of tyloxapol, with or without 25 admixing an anti-inflammatory glucocorticoid, in an acceptable ointment to the affected area.

The appended claims set forth various novel and useful features of the invention.

## CLAIMS:

1. A method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B in a mammal comprising administering to a mammal an effective amount of a compound of the formula:



where R = ethylene, R' = C<sub>4</sub> to C<sub>14</sub> straight chain or branched alkyl, x is greater than 1, and y = 8 to 18, effective to inhibit oxidant chemical reactions caused by the oxidant species in the mammal, thereby treating the mammalian disease entities to prevent production of NF- $\kappa$ B.

2. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 1 wherein said compound is tyloxapol.

3. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 1 wherein said administering comprises administering directly to the mammal's respiratory tract.

4. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 1 wherein said administering comprises administering said compound by aerosolization.


-35-

5. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 1 wherein said administering of said compound includes administering in a physiologically acceptable carrier.

6. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 1 wherein said administering further comprises administering a nonpolymeric alkyl or aryl alcohol.

7. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 6 wherein said alcohol is cetyl alcohol and said cetyl alcohol is added in an amount equivalent to 1 to 1.5 times the weight of said compound.

8. A method of treating cutaneous inflammatory disorders in a mammal comprising administering to a mammal an effective amount of a compound of the formula:




where R = ethylene, R' = C<sub>4</sub> to C<sub>14</sub> straight chain or branched alkyl, x is greater than 1, and y = 8 to 18, effective to inhibit oxidant chemical reactions caused by the oxidant species in the mammal, thereby treating the mammalian disease entities to the affected skin area.

9. The method of treating cutaneous inflammatory disorders according to Claim 8 wherein said compound is tyloxapol.

10. The method of treating cutaneous inflammatory disorders according to Claim 8 wherein said administering of said compound includes administering in a physiologically acceptable carrier.

11. The method of treating cutaneous inflammatory disorders according to Claim 10 wherein said carrier is a petroleum based ointment.

12. A method for inhibiting secretion of the pro-inflammatory cytokines TNF, IL-1, IL-6, IL-8 and the growth factor GM-CSF, said method comprising administering to a mammal an effective amount of a compound of the formula:



where R = ethylene, R' = C<sub>4</sub> to C<sub>14</sub> straight chain or branched alkyl, x is greater than 1, and y = 8 to 18, effective to inhibit oxidant chemical reactions caused by the oxidant species in the mammal, thereby treating the mammalian disease entities to inhibit secretion of said pro-inflammatory cytokines.

13. The method of inhibiting secretion of pro-inflammatory cytokines according to Claim 12 wherein said compound is tyloxapol.

-37-

14. The method of inhibiting secretion of pro-inflammatory cytokines according to Claim 12 wherein said administering comprises administering directly to the mammal's respiratory tract.


15. The method of inhibiting secretion of pro-inflammatory cytokines according to Claim 12 wherein said administering said compound is by aerosolization.

16. The method of inhibiting secretion of pro-inflammatory cytokines according to Claim 12 wherein said administering of said compound includes administering in a physiologically acceptable carrier.

17. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 12 wherein said administering further comprises administering a nonpolymeric alkyl or aryl alcohol.

18. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 17 wherein said alcohol is cetyl alcohol and said cetyl alcohol is added in an amount equivalent to 1 to 1.5 times the weight of said compound.

19. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B, said method comprising administrating to a mammal an effective amount of a compound of the formula:



where R = ethylene, R' = C<sub>1</sub> to C<sub>14</sub> straight chain or branched alkyl, x is greater than 1, and y = 8 to 18, effective to inhibit oxidant chemical reactions caused by the oxidant species in the mammal, thereby treating the mammalian disease entities to prevent production of NF- $\kappa$ B, and an effective amount of an anti-inflammatory steroid to inhibit steroid resistance.

20. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 19 wherein said steroid is selected from the group consisting of methylprednisolone, triamcinolone, beclomethasone dipropionate, flunisolide or dexamethasone.

21. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 19 wherein said compound is tyloxapol.

22. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 19 wherein said administering comprises administering by aerosolization.

-39-

23. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 19 wherein said compound and said steroid are administered in a physiologically acceptable carrier.

24. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 19 wherein said compound is tyloxapol, said anti-inflammatory steroid is methylprednisolone, and the ratio of said tyloxapol to said methylprednisolone is 5 mg. to 25 mg.

25. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 19 wherein said compound is tyloxapol, said anti-inflammatory steroid is triamcinolone, and the ratio of said tyloxapol to said triamcinolone is 5 mg. to 25 mg.


26. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 19 wherein said compound is tyloxapol, said anti-inflammatory steroid is beclomethasone dipropionate, and the ratio of said tyloxapol to said beclomethasone dipropionate is 6 mg. to 25 mg.

27. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 19 wherein said compound is tyloxapol, said anti-inflammatory steroid is flunisolide, and the ratio of said tyloxapol to said flunisolide is 125 mg. to 250 mg.

-40-

28. The method of inhibiting activation of nuclear transcription factor NF- $\kappa$ B according to Claim 19 wherein said compound is tyloxapol, said anti-inflammatory steroid is dexamethasone, and the ratio of said tyloxapol to said dexamethasone is 125 mg. to 250 mg.

29. The method of inhibiting leukotrienes, said method comprising administrating to a mammal an effective amount of a compound of the formula:



where R = ethylene, R' = C<sub>4</sub> to C<sub>14</sub> straight chain or branched alkyl, x is greater than 1, and y = 8 to 18, effective to inhibit oxidant chemical reactions caused by the oxidant species in the mammal, thereby treating the mammalian disease entities to prevent production of leukotrienes.

1/8






FIG. I.

SUBSTITUTE SHEET (RULE 26)

2/8



3/8




FIG. 4.

SUBSTITUTE SHEET (RULE 26)




FIG. 5A.




FIG. 5B.

SUBSTITUTE SHEET (RULE 26)

5/8




Ctl

IL-1 $\beta$ IL-1 $\beta$  + Tyloxapol $H_2O_2$  $H_2O_2$  + Tyloxapol

Competition

↑  
AP-1↑  
NF- $\kappa$ BFIG. 6.

SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)




FIG. 8A.




FIG. 8B.




FIG. 8C.

8/8




FIG. 8D.






FIG. 8E.

SUBSTITUTE SHEET (RULE 26)



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  A61K 31/765		A3	(11) International Publication Number: <b>WO 97/38699</b>  (43) International Publication Date: 23 October 1997 (23.10.97)															
(21) International Application Number: PCT/US97/06150  (22) International Filing Date: 14 April 1997 (14.04.97)		(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).																
(30) Priority Data: 08/632,275 15 April 1996 (15.04.96) US  (60) Parent Application or Grant (63) Related by Continuation US Filed on 08/632,275 (CON) 15 April 1996 (15.04.96)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.																
(71) Applicant (for all designated States except US): CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY doing business as CAROLINAS MEDICAL CENTER [US/US]; P.O. Box 32861, Charlotte, NC 32861 (US).		(88) Date of publication of the international search report: 24 December 1997 (24.12.97)																
(72) Inventors; and (75) Inventors/Applicants (for US only): GHILO, Andrew, J. [US/US]; 211 Brandermill Drive, Durham, NC 27713 (US). KENNEDY, Thomas, P. [US/US]; 213 Grande Drive, Richmond, VA 23229 (US).																		
(74) Agents: McCOY, Michael, D. et al.; Bell, Seltzer, Park & Gibson, P.O. Drawer 34009, Charlotte, NC 28234 (US).																		
(54) Title: USE OF ALKYLARYL POLYETHER ALCOHOL POLYMERS FOR THE TREATMENT OF CHRONIC PULMONARY INFLAMMATION																		
<p>(57) Abstract</p> <p>A method and medicant for the inhibition of activation of the nuclear transcription NF-<math>\kappa</math>B comprising administering an effective amount of a compound of formula (I) where R = ethylene, R' = C<sub>4</sub> to C<sub>14</sub> straight chain or branched alkyl, x is greater than 1, and y = 8 to 18, is provided. The medicant is preferably administered by aerosolization into the mammalian respiratory system. The medicant may also be applied to the mammalian skin. Preferably, the medicant includes a physiologically acceptable carrier which may be selected from buffered saline, isotonic saline, normal saline, petroleum-based ointments and U.S.P. cold cream. There is further provided a method wherein said medicant includes an anti-inflammatory steroid. In addition, a method and medicant for treating cutaneous inflammatory disorders, inhibiting the secretion of the pro-inflammatory cytokines TNF, IL-1, IL-6, IL-8 and the growth factor GM-CSF, is provided.</p>																		
<div style="text-align: center;">     <table border="1"> <caption>Data from Bar Chart</caption> <thead> <tr> <th>Treatment</th> <th>2,5 DIHYDROXYBENZOIC ACID (PM/ml x 10<sup>2</sup>)</th> <th>2,3 DIHYDROXYBENZOIC ACID (PM/ml x 10<sup>2</sup>)</th> </tr> </thead> <tbody> <tr> <td>NORMAL SALINE</td> <td>~8.0</td> <td>~6.8</td> </tr> <tr> <td>TYLOXAPOL 0.1mg/ml</td> <td>~4.5</td> <td>~4.6</td> </tr> <tr> <td>TYLOXAPOL 1.0mg/ml</td> <td>~3.5</td> <td>~3.2</td> </tr> <tr> <td>TYLOXAPOL 10.0mg/ml</td> <td>~1.9</td> <td>~2.0</td> </tr> </tbody> </table> </div>				Treatment	2,5 DIHYDROXYBENZOIC ACID (PM/ml x 10 <sup>2</sup> )	2,3 DIHYDROXYBENZOIC ACID (PM/ml x 10 <sup>2</sup> )	NORMAL SALINE	~8.0	~6.8	TYLOXAPOL 0.1mg/ml	~4.5	~4.6	TYLOXAPOL 1.0mg/ml	~3.5	~3.2	TYLOXAPOL 10.0mg/ml	~1.9	~2.0
Treatment	2,5 DIHYDROXYBENZOIC ACID (PM/ml x 10 <sup>2</sup> )	2,3 DIHYDROXYBENZOIC ACID (PM/ml x 10 <sup>2</sup> )																
NORMAL SALINE	~8.0	~6.8																
TYLOXAPOL 0.1mg/ml	~4.5	~4.6																
TYLOXAPOL 1.0mg/ml	~3.5	~3.2																
TYLOXAPOL 10.0mg/ml	~1.9	~2.0																

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/US 97/06150A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K31/765

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 474 760 A (GHIO ET AL.) 12 December 1995 cited in the application see the whole document ---	1-18
P, X	A.J. GHIO ET AL.: "Tyloxapol inhibits NF- $\kappa$ B and cytokine release, scavenges HOCl and reduces viscosity of cystic fibrosis sputum." AM. J. RESPIR. CRITICAL CARE MED., vol. 154, no. 3-I, 1996, pages 783-788, XP002044936 see the whole document ---	1-7, 12-18

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

1

Date of the actual completion of the international search

29 October 1997

Date of mailing of the international search report

11.11.97

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax: (+31-70) 340-3016

## Authorized officer

Klaver, T

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	M.J. THOMASSEN ET AL.: "Regulation of human alveolar macrophage inflammatory cytokines by tyloxapol, a component of the synthetic surfactant exosurf." CLIN. IMMUNOL. IMMUNOPATH., vol. 77, no. 2, 1995, pages 201-205, XP002044937 see the whole document ---	1,2,12, 13
X	M.J. THOMASSEN ET AL.: "Characterization of exosurf(surfactant)-mediated suppression of stimulated human alveolar macrophage cytokine responses." AM. J. RESPIR. CELL. MOL. BIOL., vol. 10, no. 4, 1994, pages 399-404, XP002044938 see the whole document ---	1,2,12, 13
X	O.P. SCHMIDT : "Aerosoltherapie bei chronischen atemwegskrankheiten." ATEMWEGS- UND LUNGENERKRANKUNGEN, vol. 5, no. 1, 1979, pages 28-34, XP002044939 see the whole document ---	1-5, 12-16
A	US 5 362 758 A (AHMED) 8 November 1994 ---	19-29
A	US 5 308 611 A (THOMPSON) 3 May 1994 -----	
1		

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 97/06150

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5474760 A	12-12-95	AU 679224 B CA 2159485 A EP 0693921 A JP 8508504 T AU 6527394 A CA 2102142 A WO 9422425 A US 5512270 A	26-06-97 13-10-94 31-01-96 10-09-96 24-10-94 01-10-94 13-10-94 30-04-96
US 5362758 A	08-11-94	NONE	
US 5308611 A	03-05-94	CA 2038251 A	15-09-91

